-+ 0.00%
-+ 0.00%
-+ 0.00%

Exelixis' Partner Ipsen Received A Positive Opinion From The European Medicine Agency's Committee For Medicinal Products For Human Use For Cabometyx (Cabozantinib) For Adult Patients With Previously Treated Advanced Neuroendocrine Tumors

Benzinga·06/20/2025 10:56:27
Listen to the news
  • A regulatory decision by the European Medicines Agency is anticipated in 2025.
  • In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting.